E. J. Czerwiński
YOU?
Author Swipe
View article: SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial
SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial Open
View article: When can secondary osteoporosis be suspected based on the result of a densitometry test? Results from a 10-year observation of 1,200 women over the age of 50 from the Malopolska region
When can secondary osteoporosis be suspected based on the result of a densitometry test? Results from a 10-year observation of 1,200 women over the age of 50 from the Malopolska region Open
View article: Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12 Open
Context SB16 is a proposed biosimilar to reference denosumab (DEN; brand name: Prolia). Objective This phase 3 randomized, double-blind, multicenter study evaluated the biosimilarity of SB16 to DEN in women with postmenopausal osteoporosis…
View article: Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis Open
View article: Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study Open
Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC). The objective of this study was to evaluate the efficacy and safety of the abaloparatide microstructured transdermal system (aba…
View article: Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial Open
View article: Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe
Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe Open
View article: The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial Open
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo. The Abaloparatide for the Treatment of …
View article: The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study
The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study Open
View article: Relation between risk of falls, sarcopenia and parameters assessing quality of skeletal muscles in a group of postmenopausal women
Relation between risk of falls, sarcopenia and parameters assessing quality of skeletal muscles in a group of postmenopausal women Open
The decrease of muscle mass is significantly correlated with the risk of falls in the last year in postmenopausal women. Impact of sarcopenia on the risk of falls depends on diagnostic criteria.
View article: Osteoporoza - zapomniana choroba milionów złamań
Osteoporoza - zapomniana choroba milionów złamań Open
View article: Relationship Between Bone Mineral Density <i>T</i>-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
Relationship Between Bone Mineral Density <i>T</i>-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment Open
Although treat-to-target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to reduce fracture risk maximally. We investigated the relationship between total hip BMD T-score and the incide…
View article: Trabecular Bone Score (TBS) in Clinical Practice – Rewiev
Trabecular Bone Score (TBS) in Clinical Practice – Rewiev Open
Bone mineral density (BMD) assessment is the basic method for assessing fracture risk and diagnosing osteoporosis according to the World Health Organization (WHO). Osteoporosis is diagnosed when the T-score at the proximal femur or spine i…
View article: Тезисы III Международного симпозиума «Заболевания костей и суставов и возраст» (12-14 марта 2018, г. Львов, Украина)
Тезисы III Международного симпозиума «Заболевания костей и суставов и возраст» (12-14 марта 2018, г. Львов, Украина) Open
.
View article: Vertebral fracture assessment, trabecular bone score and handgrip in a group of postmenopausal women with vertebral fractures – preliminary study
Vertebral fracture assessment, trabecular bone score and handgrip in a group of postmenopausal women with vertebral fractures – preliminary study Open
Objectives The aim of our study was to determine a possible correlation between vertebral fractures (indicated by VFA – vertebral fracture assessment), TBS (trabecular bone score) and muscle strength (measured by means of handgrip strength…
View article: Contemporary Management of Osteoporotic Fractures
Contemporary Management of Osteoporotic Fractures Open
With aging of the population, osteoporotic fractures are becoming an increasing medical problem worldwide. It has been estimated that 2,700,000 patients experienced a low energy fracture in the Polish population in 2010. On the basis of c…
View article: Patterns in the Diagnosis and Treatment of Osteoporosis in Men: A Questionnaire-based Survey in Central and Eastern European Countries
Patterns in the Diagnosis and Treatment of Osteoporosis in Men: A Questionnaire-based Survey in Central and Eastern European Countries Open
Summary To assess the current practice patterns in the diagnosis and treatment of male osteoporosis based on questionnaires. Questionnaires were presented and filled out by osteoporosis experts from Austria, Bulgaria, the Czech Republic, H…
View article: 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension Open
View article: EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures
EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures Open
View article: Fracture Liaison Services - Polish Experience. Methods of Secondary Prevention of Osteoporotic Fractures
Fracture Liaison Services - Polish Experience. Methods of Secondary Prevention of Osteoporotic Fractures Open
Background. Fragility fractures are a major challenge to health systems around the world. The risk of a subsequent fracture may increase even 11-fold after one’s first fracture event. A coordinator-based system (Fracture Liaison Services) …
View article: The role of calcium supplementation in healthy musculoskeletal ageing
The role of calcium supplementation in healthy musculoskeletal ageing Open
View article: Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Romosozumab Treatment in Postmenopausal Women with Osteoporosis Open
In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen…
View article: FRACTURE LIAISON SERVICE. OUR EXPERIENCE IN POLAND
FRACTURE LIAISON SERVICE. OUR EXPERIENCE IN POLAND Open
Fractures are the essential problem of osteoporosis, therefore identification of patient at risk is crucial. This is widely known that patients with higher risk, increased in these group 2 to 6 times. Orthopedic surgeon is the first and us…
View article: Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates Open
In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greater BMD increases at all measured skeletal sites and greater inhibition of bone remodeling compared with ZOL.
View article: Possibilities for Implementing Fracture Liaison Service in Poland in the Light of a Visit to Glasgow Western Infirmary
Possibilities for Implementing Fracture Liaison Service in Poland in the Light of a Visit to Glasgow Western Infirmary Open
Osteoporosis remains one of the top challenges for health services all over the world. Osteoporotic changes in bone structure along with the aging of society result in rapid growth of osteoporotic fractures. Statistics show that approximat…
View article: The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study Open
View article: Cost-effectiveness Analysis of Treatment of Osteoporotic Fractures in Relation to FRAX Algorithm in a Sample of Polish Population
Cost-effectiveness Analysis of Treatment of Osteoporotic Fractures in Relation to FRAX Algorithm in a Sample of Polish Population Open
1. The study showed pharmacological treatment to be cost-effective in a large group of patients forming the study population. 2. The analysis also revealed a strong correlation between study results and the specific tool employed to define…
View article: A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial
A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial Open
In men with low BMD, denosumab treatment for a second year continued to increase BMD, maintained reductions in bone resorption, and was well tolerated. BMD increased in men initiating denosumab during the second year. These effects were si…